0001764013-24-000083.txt : 20240419
0001764013-24-000083.hdr.sgml : 20240419
20240419180659
ACCESSION NUMBER: 0001764013-24-000083
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240417
FILED AS OF DATE: 20240419
DATE AS OF CHANGE: 20240419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levine Mark S.
CENTRAL INDEX KEY: 0001617236
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 24859120
MAIL ADDRESS:
STREET 1: 1601 TRAPELO ROAD
STREET 2: SUITE 284
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wk-form4_1713564410.xml
FORM 4
X0508
4
2024-04-17
0
0001764013
Immunovant, Inc.
IMVT
0001617236
Levine Mark S.
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
0
1
0
0
Chief Legal Officer
0
Common Stock
2024-04-17
4
S
0
7602
28.80
D
349344
D
Common Stock
2024-04-17
4
S
0
2225
29.94
D
347119
D
On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine
2024-04-19